Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003005356 | SCV003302487 | uncertain significance | not provided | 2022-11-08 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 508 of the VPS13A protein (p.Pro508Leu). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with VPS13A-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004963342 | SCV005531671 | uncertain significance | Inborn genetic diseases | 2024-07-02 | criteria provided, single submitter | clinical testing | The c.1523C>T (p.P508L) alteration is located in exon 17 (coding exon 17) of the VPS13A gene. This alteration results from a C to T substitution at nucleotide position 1523, causing the proline (P) at amino acid position 508 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |